and frailty are commonly encountered in patients with end-stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait-list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated. We aim to ascertain the change in their prevalence over time on the wait list and determine their impact on hospitalization, delisting, and wait-list survival, specifically for patients with nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD). Adult patients who were evaluated for their first liver transplant from 2014 to 2016 with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Computed tomography scans were used to determine the presence of sarcopenia and myosteatosis. Frailty was diagnosed using the Rockwood frailty index. Patients with NASH had a significantly lower prevalence of sarcopenia (22% versus 47%; P < 0.001) but a significantly higher prevalence of frailty (49% versus 34%; P = 0.03) when compared with patients with ALD at the time of listing. In patients with NASH, sarcopenia was not associated with adverse events, but a higher frailty score was associated with an increased length of hospitalization (P = 0.05) and an increased risk of delisting (P = 0.02). In patients with ALD, univariate analysis showed the presence of sarcopenia was associated with an increased risk of delisting (P = 0.01). In conclusion, sarcopenia and frailty occur with differing prevalence with variable impact on outcomes in wait-listed patients with NASH and ALD.
generalized loss of skeletal muscle mass, strength, and function. (1) Sarcopenia is linked but not equivalent with frailty, defined as an increased vulnerability to stressors due to a decline in physiological reserve. (2) Both entities have been associated with adverse clinical outcomes, including increased risk of decompensation and increased wait-list mortality when analyzed in all wait-listed patients. (2) Sarcopenia has also been associated with a longer hospitalization, longer intensive care unit (ICU) stay, and an increased risk of mortality after liver transplantation (LT). (3) Thus far, studies have not evaluated the differences in prevalence and impact of sarcopenia or frailty in patients with varying etiologies for ESLD. Evidence suggests an overlap in the pathophysiology of nonalcoholic steatohepatitis (NASH) and sarcopenia with insulin resistance and increased inflammation playing a key role in both processes. (4) As a result, the presence of one increases the risk for the other. For example, Original article | 15 patients with sarcopenia have a 3-fold increased risk of having nonalcoholic fatty liver disease (NAFLD), (5) and patients with NAFLD have a 6-fold increased risk of having sarcopenic obesity. (6) Studies have also suggested that patients with alcoholic liver disease (ALD) may have an increased prevalence of sarcopenia. (7) In these patients, both advanced liver disease and direct effects of alcohol contribute to sarcopenia. For instance, alcohol leads to a state of anabolic resistance whereby there is inadequate stimulation of protein synthesis in the presence of adequate nutrient or protein intake. (8) Alcohol also impairs skeletal muscle mitochondrial function leading to impaired protein synthesis, (9) as well as leading to hypogonadism and its effects on muscle. (10) Finally, alcohol inhibits mammalian target of rapamycin complex 1, which suppresses autophagy and stimulates protein synthesis. (8) All of these effects combine to affect muscle size and function. Comorbidities that may contribute to frailty include age, metabolic, cardiovascular or renal disease, among others. Thus, it is likely the prevalence and impact of both sarcopenia and frailty may differ in populations of patients with ESLD. Analyzing these entities in specific populations is needed to better understand the risk and management of sarcopenia and frailty specific to those individuals.
We aim to ascertain the prevalence of sarcopenia and frailty in 2 leading indications for transplantation, NASH and ALD, and to determine their impact on decompensation, hospital length of stay (LOS) prior to transplant, delisting, and wait-list survival.
Patients and Methods

patients
This retrospective study included 265 adult patients evaluated and listed for their first LT from 2014 to 2016 at Mayo Clinic, Rochester, MN. All adults over 18 years with a primary diagnosis of NASH (n = 136) or ALD (n = 129) were included. Patients who had LT assessment for other etiologies, acute liver failure, or for multivisceral transplant were excluded.
Using an institutional review board-approved protocol, data on demographics, ICU stay, hospitalizations including cause and cumulative LOS for these hospitalizations, decompensation (encephalopathy, ascites, spontaneous bacterial peritonitis, variceal bleed, and hepatorenal syndrome), immunosuppression, renal function, date of LT, date of delisting, cause of delisting, last follow-up, and cause of and date of death were collected from patient charts. LOS was defined as mean length of all hospitalizations on the wait list.
sarcOpenia anD MYOsteatOsis assessMent
Computed tomography (CT) scans of the abdomen ordered at the time of transplant evaluation and then at the discretion of the clinician for hepatocellular carcinoma screening were obtained. CT images were read by a single reviewer (R.A.B.), blinded to outcome, using the software BodyCompSlicer (developed at Mayo Clinic, Rochester, MN), which is comparable to sliceOmatic (TomoVision, Montreal, Canada). (11) The reviewer selected the CT slice at the third lumbar (L3) region. BodyCompSlicer automatically placed 3 boundary lines between external air and subcutaneous fat, between subcutaneous fat and abdominal wall/paraspinal muscles, and between abdominal wall/paraspinal muscles and visceral fat (Supporting Fig. 1A ). The reviewer carefully inspected each boundary and made necessary corrections (Supporting Fig. 1B ). The following muscles were outlined: psoas, paraspinal, and the abdominal wall (including rectus abdominis, transverse abdominis, and internal and external oblique) muscles. The software then calculated the skeletal muscle area, as area containing pixels between boundary 2 and 3, excluding the spine, and having a CT attenuation value of -30 to 150 Hounsfield units (HU). The L3 skeletal muscle area was then normalized to height to calculate the third lumbar skeletal muscle index (L3SMI). Sarcopenia was defined as skeletal muscle index (SMI) <50 cm 2 /m 2 in men and <39 cm 2 /m 2 in women. (12) The same method was used for the repeat CT scans, thus allowing the L3SMI to be compared at differing time points, to determine what changes occurred in body composition while awaiting LT.
Myosteatosis or fat infiltration of the muscles was indirectly measured by muscle attenuation. Mean muscle attenuation in HU was reported for the entire muscle area at the L3 vertebra. We defined myosteatosis as <41 HU in patients with a body mass index (BMI) up to 24.9 kg/m 2 and <33 in those with a BMI ≥25 kg/m 2 . These cutoff values have been shown to be associated with mortality in patients with malignancy and in patients with cirrhosis. (13, 14) 
FrailtY assessMent
Frailty was defined as a score of 0.25 or greater using the deficit index, as previously described by Rockwood et al. (15) A similar cutoff was used when assessing the impact of frailty on survival in lung transplant patients. (16) Because of its continuous nature, the deficit index is better able to discriminate between moderate and severe frailty, (17) and it may be more sensitive to modifications and thus a useful tool for monitoring responses to intervention in comparison to the Fried frailty index, which is on a categorical scale. Both indices assess for weight loss, physical stamina, and function. They also have significant overlap in identifying frailty and have statistical convergence. (17) This score is calculated by dividing the total number of deficits present by the total number of deficits possible (32 deficits). The frailty score ranges from 0 to 1, or from no deficits (score = 0) to all (32/32; score = 1) possible deficits present (Appendix 1).
Questionnaires completed by patients during their pre-LT visit were used to determine the items representing activities of daily living. (14) Items representing comorbidities (18) were collected using a manual chart review. If more than 1 question was unanswered or if the questionnaire was not within 1 year of LT evaluation, the deficit index was not calculated. In cases where 1 of the items from the questionnaire was missing, the denominator was adjusted to 31. Only the pre-LT deficit index was calculated; this was not measured over time.
DeFinitiOns OF cOMOrBiDities
A patient was classified as being underweight, if their BMI was <18.5 kg/m 2 ; overweight, if their BMI was between 25 and 29.9 kg/m 2 ; and obese, if their BMI was 30 kg/m 2 or more. Anemia was defined as a hemoglobin concentration of <12.0 g/dL in women and <13.0 g/dL in men. Moderate and severe renal insufficiency was defined as an estimated glomerular filtration rate of 30-60 mL/minute and <30 mL/minute, respectively. Other comorbidities were defined based on documentation of diagnosis in the patient chart.
statistical analYsis
Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range [IQR]), and categorical variables are presented as percentages. Comparisons between groups for variables known at time of transplant evaluation were made using Student t tests or Wilcoxon rank sum tests for continuous variables and chi-square tests for categorical variables. Pre-LT and post-LT CT scans for each patient were compared using paired t tests or McNemar's tests.
Wait-list survival time was defined from the date of the LT evaluation to the date of death on the wait list (event), LT (censored), delisting for reason other than death (censored; only 3.6% [4/111] of patients were delisted for improvement in clinical condition), or last date still known to be alive on the wait list (censored), whichever occurred first. Time to delisting was defined from the date of LT evaluation to time of removal from United Network for Organ Sharing (event), date of LT (censored), or last date still known to be alive on wait list (censored). Competing risks analyses were used to estimate wait-list death (competing risks of transplant and delisting for other reasons) and delisting rates (competing risk of transplant). Cox proportional hazards regression was used to look for potential risk factors for wait-list death and delisting. Multivariate linear regression was used to determine the association between SMI, mean muscle attenuation, frailty, and LOS. For wait-list mortality, backward elimination was used to select the variables in the models because of the small number of events.
All P values were 2-sided and determined to be statistically significant at P ≤ 0.05. All statistical analyses were performed using SAS, version 9.4 (SAS Institute
Original article | 17 
Results
patient characteristics
Patients with NASH were older, were less frequently male, had a higher BMI, and had a lower Model for End-Stage Liver Disease (MELD) score at the time of listing than their counterparts (Table 1) . NASH patients were less likely to be hospitalized before LT, but overall LOS, despite fewer hospitalizations, was similar compared with the ALD cohort. Decompensation was similar between groups, but NASH patients were less likely to have ascites than patients with ALD (Table 1) . NASH patients were more commonly obese with metabolic comorbidities, and they had significantly lower HU (indicating myosteatosis; 31.1 ± 8.6 versus 34.3 ± 8.4; P < 0.01) and higher muscle mass (SMI; 51.6 cm 2 / m 2 ± 10.4 versus 48.3 cm 2 /m 2 ± 8.9; P = 0.01) on their transplant evaluation CT scans.
prevalence OF sarcOpenia anD FrailtY
Patients with NASH had a significantly lower prevalence of sarcopenia when compared with patients with ALD (22% versus 47%; P < 0.001). This difference was maintained even after adjusting for sex (NASH versus ALD; odds ratio, 0.37; 95% confidence interval [CI], 0.21-0.64; P < 0.001, adjusted for sex). Sarcopenic patients had a significantly lower BMI in both NASH (28.0 ± 6.4 kg/m 2 versus 37.0 ± 7.3 kg/ m 2 ; P < 0.001) and ALD (25.5 ± 3.7 kg/m 2 versus 29.5 ± 5.4 kg/m 2 ; P < 0.001; Table 2 ). Sex differences in sarcopenia versus no sarcopenia were noted in both NASH (sarcopenic versus nonsarcopenic; 70% male versus 45% male; P = 0.02) and ALD patients (sarcopenic versus nonsarcopenic; 78% male versus 62% male; P = 0.04). Finally, there was no age difference in NASH patients with and without sarcopenia (61.7 ± 9.4 years versus 59.7 ± 7.3 years; P = 0.06). However, ALD patients with sarcopenia were older (56.4 ± 9.0 years versus 51.4 ± 10.9 years; P < 0.01).
Patients with NASH had a significantly higher prevalence of frailty when compared with patients with ALD (49% versus 34%; P = 0.03) ( Table 1) . NOTE: Data are given as n (%) or mean ± SD unless otherwise noted. *P value from a Cox proportional hazards model.
There were no significant differences in age, BMI, or sex when comparing frail patients to nonfrail patients in either subgroup (Table 3) .
trajectOrY OF BODY cOMpOsitiOn changes On the Wait list
There were 73 patients who had a repeat CT while awaiting transplant (NASH, n = 39; ALD, n = 34) at a median time of 1 year (IQR, 0.74-1.32 years).
The changes in sarcopenia and myosteatosis are shown in Fig. 1 . When comparing muscle quality and quantity between these CTs, there was no significant change in muscle mass (SMI) in either the NASH (median, 0.3 cm 2 /m 2 ; IQR, -1.8 to 4.9; P = 0.28) or the ALD (median, -0.2 cm 2 /m 2 ; IQR, -3.0 to 4.3; P = 0.94) patients. There was no significant difference in the change in mean HU (myosteatosis) between the NASH (median, -0.7 HU; IQR, -6.8 to 5.4) and the ALD patients (median, 2.7 HU; IQR, -2.3 to 7.9; P = 0.04). However, when looking at the change in 
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mean HU (myosteatosis) in the ALD patients, there was a significant change (median, −0.7 HU; IQR, −6.8 to 5.4; P = 0.04), but this was not seen in the NASH group (median, −0.7 HU; IQR, −6.8 to 5.4; P = 0.86). Because the timing of the second CT varied for each patient, we also looked at percentage change per 100 days to enable comparison between patients. Again, there was no significant difference in percentage change in muscle mass (according to SMI) per 100 days in either the NASH (mean ± SD, 0.8% ± 4.0%; P = 0.39) or the ALD (-0.4% ± 4.2%; P = 0.80) patients. There was no significant difference in percentage change in mean HU (myosteatosis) per 100 days in the NASH (mean ± SD, -1.6% ± 16.2%; P = 0.66) or the ALD (2% ± 8.4%; P = 0.07) groups.
iMpact OF sarcOpenia anD FrailtY On pre-lt hOspitaliZatiOn lOs
Although ALD patients were more frequently hospitalized (60.5% versus 41.2%; P < 0.01), the average LOS for all hospitalizations was similar between patients with NASH and ALD (11.0 days ± 10.7 versus 13.3 days ± 13.6; P = 0.24, respectively). The majority (53%; 204/388) of the hospitalizations were for decompensated liver disease, followed by other causes (39%; 151/388), which included acute kidney injury, infection, hernia repair, GI bleed, and chest pain. Causes for hospitalization were multifactorial, and the main cause was unclear in a minority of patients (9%; 33/388). The presence of sarcopenia did not have an impact on the LOS in patients with either ALD or NASH. In multivariate linear regression, neither MELD, muscle mass (SMI), nor mean HU (myosteatosis) were significantly associated with the pre-LT LOS in the ALD or NASH population (Table 4 ).
However, in NASH patients, multivariate linear regression showed for every 0.1 unit increase in frailty deficit index, LOS increased by 2.7 days (95% CI, -0.01 to 5.45; P = 0.05). No such associations were seen in the ALD patients.
iMpact OF sarcOpenia anD FrailtY On Delisting
There was no significant difference in the risk of delisting in the NASH group when compared with the ALD group (1-year cumulative incidence 13 
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(for reasons other than transplant) in the 2 groups (data not shown). Death was the most common cause for delisting in both groups (n = 14 [33%] for NASH and n = 29 [42%] for ALD), followed by debility (n = 9 [21%] for NASH and n = 10 [14%] for ALD). Delisting due to other causes occurred in 46% of patients with NASH and 44% of patients with ALD. In NASH patients, multivariate analysis showed neither muscle mass (SMI; P = 0.25) nor mean HU (myosteatosis; P = 0.20) had an impact on delisting. Similarly, in univariate analysis, muscle mass (according to SMI) was not associated with either risk of delisting (P = 0.28) or death (P = 0.12). In patients with ALD, muscle mass (according to SMI) was associated with an increased risk of delisting (HR, 1.9; 95% CI, 1.2-3.1; P = 0.01) in univariate analysis (Fig. 2) , but it was not associated with risk of death (P = 0.06). Similarly, in univariate analysis, muscle mass (according to SMI) was not associated with either risk of delisting (P = 0.28) or death (P = 0.12). However, in multivariate analysis neither MELD, muscle mass (SMI), nor mean HU (myosteatosis) was significantly associated with delisting (Table 5) .
Frailty was significantly associated with delisting on multivariate analysis in patients with NASH. For every 0.1-unit increase in the frailty deficit index, the risk of delisting was 1.46 times higher (95% CI, 1.06-2.03; P = 0.02; Table 5 ). In contrast, in patients with ALD, frailty did not impact delisting.
iMpact OF sarcOpenia anD FrailtY On Wait-list sUrvival
Patients with NASH had a numerically but not statistically lower risk of death on the wait list when compared with patients with ALD, (cumulative incidence at 1 year, 7.4% [95% CI, 3.1-11.5] versus 20.2% [95% CI, 12.8-26.9]; HR, 0.53; 95% CI, 0.28-1.01; P = 0.05). In NASH patients, sarcopenia did not impact wait-list survival (HR, 2.1; 95% CI, 0.7-6.3; P = 0.21, adjusted for mean HU [myosteatosis]). Both age (per 10 years; HR, 3.24; 95% CI, 1.07-9.78; P = 0.04, adjusted for MELD) and MELD score (per point; HR, 1.11; 95% CI, 1.03-1.20; P = 0.01, adjusted for age) were associated with increased risk of death on the wait list on multivariate analysis. In patients with ALD, those with sarcopenia had an increased risk of death on the wait list. However, this difference was not statistically significant (HR, 2.08; 95% CI, 0.98-4.41; P = 0.06) using univariate analysis (Fig. 2) . In multivariate analysis, only MELD score was significantly associated with death on the wait list (HR, 1.07; 95% CI, 1.003-1.15; P = 0.04, adjusted for age and mean HU [myosteatosis]). The most common causes for death in NASH patients were liver failure (24%), followed by infection (19%), unknown (29%), and other causes (29%; including hemorrhage, cancer, cardiovascular disease [CVD], and accidental deaths). Similarly, in patients with ALD, the most common cause for death was related to liver failure (20%), followed by infection (13%), unknown (33%), and other causes (34%, including hemorrhage, cancer, CVD, and accidental deaths).
When comparing frail to nonfrail patients, there was no significant difference in death occurring while on the wait list for either NASH (HR, 0.89, 95% CI, 0.31-2.58, P = 0.83) or ALD patients (HR, 1.04, 95% CI, 0.46-2.32; P = 0.93; Supporting Fig. 2) . No frailty index cutoff point could be identified that predicted death or delisting.
Discussion
This study confirms that sarcopenia and frailty affect patient populations differently. Sarcopenia was less frequent, but frailty was more common in patients with NASH when compared with patients with ALD. Importantly, sarcopenia was associated with poor waitlist outcomes, including increased risk of delisting and worse wait-list survival, only in patients with ALD. Frailty was associated with an increased average LOS and an increased risk of wait-list removal in patients with NASH, but not in patients with ALD. These findings raise awareness that these complications are common but not synonymous and have varying impact on patient outcomes. This is the first study to address both sarcopenia and frailty in NASH and ALD populations. The prevalence of sarcopenia in NASH patients (22%) was lower than the 40%-60% reported in patients with cirrhosis of any etiology in previous studies. (18, 19) Though sarcopenia and NASH share many of the pathophysiological mechanisms, (4) it seems that there may be other factors involved that also contribute to sarcopenia. The higher BMI and increased fat stores in the NASH population may 
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partly explain the lower rates of sarcopenia in this population. Preferential loss of fat mass may spare muscle mass. (20) Patients with higher BMI may experience greater muscle work for similar activity levels than lower BMI patients, explaining the relationship seen with BMI, which may translate more frequently in the NASH population. Ascites was more common in ALD than NASH patients, which may affect the BMI measures as well as identify a more catabolic patient population. Interestingly, patients with NASH had a significantly higher prevalence of frailty (49%) when compared with patients with ALD, and this rate exceeds that of 25% reported for all patients with cirrhosis. (2) Frailty measures encompass more comorbidities than just muscle mass and reflect overall health vulnerability. It is likely that comorbidities frequently seen in NASH, such as diabetes, hypertension, CVD, or chronic sedentary lifestyle will contribute to frailty as well. Congruent with prior work, our study shows frailty is associated with an increased LOS and an increased risk of delisting in patients with NASH. (2, 21) This relationship was not seen in patients with ALD, despite the higher prevalence of sarcopenia. This may relate to the direct effect of alcohol on muscle itself and a composite of fewer comorbidities in this population.
Our study results agree with prior studies, (22) showing the presence of either sarcopenia or frailty leads to poor outcomes in patients with ESLD on the transplant wait list, whether it be increased LOS, delisting, or wait-list survival. We did not, however, find any adverse clinical outcomes associated with myosteatosis, which has previously been shown to be associated with increased LOS and poor survival. (14) Limitations of this study are its retrospective nature and the single-center patient population, which may not be representative of other centers. In this study, sarcopenia was diagnosed based solely on muscle mass because we had missing data on hand grip strength and 6-minute walk test (50%). These tools diagnose reduced muscle function, another component used in diagnosing sarcopenia. (1) Another limitation is the relatively small number of patients/events included, which makes our study underpowered to detect the associations between frailty and sarcopenia and mortality. The fact that statistical significance is found shows the strength of the association, as per previous studies that have shown both conditions are associated with poor outcomes. (2, 3) Thus, it is possible that both frailty and sarcopenia have an even greater impact in these patients. Notably, the prevalence of both frailty and sarcopenia increases with advanced liver disease, and both are influenced by age and sex. Furthermore, both entities have significant overlap in pathophysiology and are linked with sarcopenia being a key component of frailty. As a result of this, it is difficult to ascertain the clinical impact of these conditions in isolation. Our study provides justification for larger multicenter studies that are adequately powered to evaluate the association between frailty and sarcopenia and clinical outcomes in patients with varying etiologies for liver disease. Finally, frailty was defined using the deficit index developed by Rockwood et al. (15) for the geriatric population. Although this has not been used frequently in the population of patients with cirrhosis, its use in other populations has shown that it correlates with mortality. (23) Furthermore, both the Fried frailty index and the deficit index have been shown to have significant overlap in identifying frailty and have statistical convergence. (17) In conclusion, sarcopenia and frailty occur with differing prevalence in patients with NASH and ALD, suggesting further studies in these areas should account for underlying diseases and comorbidities. Both sarcopenia and frailty impact clinical outcomes in waitlisted patients differently. Furthermore, larger studies are needed to confirm these findings. It is imperative that future studies address the management of sarcopenia and frailty and the resulting impact on wait-list outcomes.
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